Paradoxically, in ovarian cancer models, EZH2 inhibition has nothing to do with the alteration of the class I antigen presentation of ovarian cancer cells (148), indicating that the regulation of EZH2 on antigen presentation may be cancer-type specific. Here, EZH2 is linked to ovarian cancer.